Differentiating vasculitis from other diseases: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 192: Line 192:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Bleeding]], [[Easy bruising|Bruisability]], [[Heart murmur]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Bleeding]], [[Easy bruising|Bruisability]], [[Heart murmur]]
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Polymyalgia rheumatica|Polymyalgia rheumatica (PMR)]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Polymyalgia rheumatica|Polymyalgia rheumatica (PMR)]]<ref name="pmid18390527">{{cite journal| author=Michet CJ, Matteson EL| title=Polymyalgia rheumatica. | journal=BMJ | year= 2008 | volume= 336 | issue= 7647 | pages= 765-9 | pmid=18390527 | doi=10.1136/bmj.39514.653588.80 | pmc=2287267 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18390527  }}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
Line 201: Line 201:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Fibrinogen|Plasma fibrinogen]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Normocytic normochromic anemia|Normocytic, normochromic anemia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[CRP]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Odontoid process|Periodontoid]] localization of [[calcification]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Vessel wall]] thickening, Increased mural contrast enhancement
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Subacromial bursitis|Subacromial]] or subdeltoid [[bursitis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |High [[Fluorescein sodium|F-FDG]] accumulation around the [[joints]] in [[Positron emission tomography|FDG PET-CT]]
!
!Small angular fibers, [[Pyknosis|Pyknotic]] [[nuclear]] clumps, or target-targetoid fibers
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Joint stiffness]], [[Fatigue]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Joint stiffness]], [[Fatigue]]
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Amyloidosis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Amyloidosis]]<ref name="pmid23227278">{{cite journal| author=Baker KR, Rice L| title=The amyloidoses: clinical features, diagnosis and treatment. | journal=Methodist Debakey Cardiovasc J | year= 2012 | volume= 8 | issue= 3 | pages= 3-7 | pmid=23227278 | doi= | pmc=3487569 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23227278  }}</ref>
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
Line 222: Line 222:
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Immunoglobulin light chains|Immunoglobulin light chain]][[Amyloid beta|(Amyloid)]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Anemia]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Normal
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ [[Creatinine|Cr]] or [[Blood urea nitrogen|BUN]],
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
↑ [[ALT]] or [[AST]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Diffusely hypoattenuating and enlarged [[liver]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Amyloid]] deposition in the media and [[adventitia]] of small arteries 
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Solid organs increased [[echogenicity]]
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |Tc-DPD for [[cardiac]] '''[[amyloid]]''' deposits
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
![[Extracellular]] deposition of [[Fibrillarin|fibrillar proteins]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Biopsy]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Cardiomegaly]], [[Dyspnea]]
|-
|-
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Diseases
Line 257: Line 258:
! rowspan="18" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Medium-Vessel Vasculitis
! rowspan="18" style="padding: 5px 5px; background: #DCDCDC;" align="center" |Medium-Vessel Vasculitis
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Polyarteritis nodosa]]
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Polyarteritis nodosa]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[ESR]], [[CRP]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Leukocytosis]], [[Normochromic anemia]], [[Thrombocytosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ [[Creatinine|Cr]] or [[Blood urea nitrogen|BUN]],
↑ [[ALT]] or [[AST]], [[Proteinuria]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 278: Line 280:
|-
|-
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis B virus]]-associated [[polyarteritis nodosa]]
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Hepatitis B virus]]-associated [[polyarteritis nodosa]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Hepatitis B surface antigen|HBsAg]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Leukocytosis]], [[Normochromic anemia]], [[Thrombocytosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ [[ALT]] or [[AST]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 299: Line 301:
|-
|-
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Kawasaki disease]]
! colspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Kawasaki disease]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 317: Line 319:
!
!
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |[[Diarrhea]], [[Vomiting]]
|-
|-
! rowspan="10" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Infectious disease]]
! rowspan="10" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Infectious disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Parvovirus B19 infection]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Parvovirus B19 infection]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 342: Line 344:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Scarlet fever]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Scarlet fever]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 363: Line 365:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Toxic shock syndrome]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Toxic shock syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 384: Line 386:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Mononucleosis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Mononucleosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 405: Line 407:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Leptospirosis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Leptospirosis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 426: Line 428:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Lyme disease|Lyme Disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Lyme disease|Lyme Disease]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 447: Line 449:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Measles]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Measles]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 468: Line 470:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Rocky Mountain Spotted Fever]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Rocky Mountain Spotted Fever]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 489: Line 491:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Staphylococcal scalded skin syndrome|Staphylococcal Scalded Skin Syndrome]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Staphylococcal scalded skin syndrome|Staphylococcal Scalded Skin Syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 510: Line 512:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Toxic Epidermal Necrolysis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Toxic Epidermal Necrolysis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 532: Line 534:
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cardiovascular disease]]
! rowspan="3" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cardiovascular disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Atrial Myxoma]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Atrial Myxoma]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 553: Line 555:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cholesterol Embolism]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Cholesterol Embolism]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 574: Line 576:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Segmental arteries|Segmental arterial]] mediolysis
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Segmental arteries|Segmental arterial]] mediolysis
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 596: Line 598:
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic disease]]
! rowspan="2" style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Systemic disease]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Antiphospholipid syndrome|Antiphospholipid Syndrome]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Antiphospholipid syndrome|Antiphospholipid Syndrome]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 617: Line 619:
|-
|-
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Juvenile Idiopathic Arthritis]]
! style="padding: 5px 5px; background: #DCDCDC;" align="center" |[[Juvenile Idiopathic Arthritis]]
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |
! style="padding: 5px 5px; background: #F5F5F5;" align="center" |

Revision as of 20:31, 27 March 2018

Vasculitis

Overview

Classification

Large-sized vessel vasculitis
Takayasu's Arteritis
Temporal Arteritis
Medium-sized vessel vasculitis
Kawasaki's Disease
Polyarteritis Nodosa
Small-sized vessel vasculitis
Churg-Strauss Syndrome
Cutaneous leukocytoclastic vasculitis
Essential cryoglobulinemic vasculitis
Henoch-Schonlein Purpura
Microscopic polyangiitis
Wegener's Granulomatosis
Variable-sized vessel vasculitis
Sjogren syndrome
Cogan syndrome
Single organ vasculitis
Primary central nervous system angiitis

Causes

Differential Diagnosis

gsEditor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:

Overview

Differential Diagnosis

Abbreviations: ABG= Arterial blood gas, ANP= Atrial natriuretic peptide, BNP= Brain natriuretic peptide, CBC= Complete blood count, COPD= Chronic obstructive pulmonary disease, CRP= C-reactive protein, CT= Computed tomography, CXR= Chest X-ray, DVT= Deep vein thrombosis, ESR= Erythrocyte sedimentation rate, HRCT= High Resolution CT, IgE= Immunoglobulin E, LDH= Lactate dehydrogenase, PCWP= Pulmonary capillary wedge pressure.

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Headache Fever Weight loss Arthralgia Claudication Bruit HTN Focal neurological disorder Biomarker CBC ESR Other CT scan Angiography Ultrasound Other
Large-Vessel Vasculitis Takayasu arteritis[1] + +/- + - + + +/- +/- ESR Leukocytosis, Anemia CRP Aneurysmal dilatation of the aorta Blood vessel stenosis Circumferential thickening of the arterial wall (Macaroni sign) PET-scan, Cardiac CT Granulomatous inflammation of arteries Arteriography Coronary aneurysm
Giant cell arteritis[2] + - + +/- - - - +/- ESR Normal CRP Stenosis, Occlusion, Dilatation Aneurysm - Mural inflammation in MRA Granulomatous inflammation of arteries Biopsy  Jaw pain and claudication
Neurological disease Cerebral aneurysm[3] + - - - - - +/- + - Normal Normal - Well-defined round, slightly hyperattenuating lesion Bulging out of the main lumen - Heterogeneous signal intensity in MRA Layers of smooth muscle cells, Intact endothelium Digital subtraction angiography (DSA) Nausea, Vomiting
Neurofibromatosis type 1[4] +/- - +/- - - - + + NF1 mutated gene Normal Normal Neurofibromin gene Bone abnormalities  Optical coherence tomography angiography (OCTA) - Optic nerve gliomas in MRI Elongated spindle-shaped cells in neurofibromas NIH diagnostic criteria Cafe au Lait spot
Neurofibromatosis type 2[5] +/- - +/- - +/- - - + NF2 mutated gene Normal Normal Schwannomin Meningioma, Schwannoma, Ependymoma Fluorescein angiography showed retinal hamartoma Localized schwannomas in nerve ultrasound Schwannoma in MRI Encapsulated biphasic nerve sheath tumor NIH diagnostic criteria Hearing loss, Vision loss
Systemic disease Fibromuscular dysplasia[6] + - +/- + + + + +/- Transforming growth factor β (TGF-β) Normal Cr or BUN Alternating stenosis and dilatations in CT angiography Stenosis in the renal arteries Luminal narrowing alternating with dilatation (Beads sign) Focal concentric, long-segment tubular stenosis or outpouching in MRA Fibrodysplastic changes, Collagen deposition Digital subtraction angiography (DSA)  Spontaneous coronary artery dissection (SCAD)
Ehlers-Danlos syndrome[7] - - - + +/- +/- - +/- TGF-β Normal Normal Cultured skin fibroblasts Multiple vascular segments with aneurysms and dissections Dissection of the posterolateral branch of the left circumflex coronary artery (LCx) Visceral arteries abnormality Vascular abnormalities in MRA Thin and rare collagen bundles in the dermis History and physical examination Bleeding, Bruisability, Heart murmur
Polymyalgia rheumatica (PMR)[8] + - +/- + - - - - Plasma fibrinogen Normocytic, normochromic anemia CRP Periodontoid localization of calcification Vessel wall thickening, Increased mural contrast enhancement Subacromial or subdeltoid bursitis High F-FDG accumulation around the joints in FDG PET-CT Small angular fibers, Pyknotic nuclear clumps, or target-targetoid fibers - Joint stiffness, Fatigue
Amyloidosis[9] +/- - - +/- +/- - + + Immunoglobulin light chain(Amyloid) Anemia Normal Cr or BUN,

ALT or AST

Diffusely hypoattenuating and enlarged liver Amyloid deposition in the media and adventitia of small arteries  Solid organs increased echogenicity Tc-DPD for cardiac amyloid deposits Extracellular deposition of fibrillar proteins Biopsy Cardiomegaly, Dyspnea
Diseases Headache Fever Weight loss Arthralgia Claudication Bruit HTN Focal neurological disorder Biomarker CBC ESR Other CT scan Angiography Ultrasound Other Histopathology Gold standard Additional findings
Medium-Vessel Vasculitis Polyarteritis nodosa + + + + + + +/- +/- ESR, CRP Leukocytosis, Normochromic anemia, Thrombocytosis Cr or BUN,

ALT or AST, Proteinuria

Hepatitis B virus-associated polyarteritis nodosa +/- +/- + + +/- +/- +/- - HBsAg Leukocytosis, Normochromic anemia, Thrombocytosis ALT or AST
Kawasaki disease - + +/- + + - +/- - Diarrhea, Vomiting
Infectious disease Parvovirus B19 infection + + + + - - - +/-
Scarlet fever + + +/- + - - - -
Toxic shock syndrome + + + + - - - +/-
Mononucleosis + + + + - - - -
Leptospirosis + + + + +/- - - -
Lyme Disease +/- + +/- + +/- - - -
Measles +/- + +/- + - - - -
Rocky Mountain Spotted Fever + + + + - - - -
Staphylococcal Scalded Skin Syndrome + + + + - - +/- +/-
Toxic Epidermal Necrolysis - + + - - - - +/-
Cardiovascular disease Atrial Myxoma - - +/- - - - - +/-
Cholesterol Embolism +/- +/- - - + - - +
Segmental arterial mediolysis + - - - + + + +/-
Systemic disease Antiphospholipid Syndrome + + - - - - - +/-
Juvenile Idiopathic Arthritis - - - + +/- - - -
Diseases Headache Fever Weight loss Arthralgia Claudication Bruit HTN Focal neurological disorder Biomarker CBC ESR Other CT scan Angiography Ultrasound Other Histopathology Gold standard Additional findings
Small-Vessel Vasculitis ANCA-associated vasculitis Microscopic polyangiitis
Granulomatosis with polyangiitis (Wegener’s)
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
Hydralazine-associated ANCA-associated vasculitis
Immune complex small-vessel vasculitis Anti-glomerular basement membrane disease
Cryoglobulinemic vasculitis
Hepatitis C virus-associated cryoglobulinemic vasculitis
IgA vasculitis (Henoch-Schönlein purpura)
Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis)
Gastrointestinal disease Acute mesenteric ischemia
Cardiovascular disease Infective Endocarditis
Leukocytoclastic Vasculitis
Pulmonary disease Langerhans Cell Histiocytosis
Lung Abscess
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Asthma
Pulmonary Infarction
Renal disease Acute Poststreptococcal Glomerulonephritis
Hematologic disease Hemolytic-Uremic Syndrome
Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma
Hypereosinophilic Syndrome
Non-Hodgkin Lymphoma
Serum Sickness
Disseminated Intravascular Coagulation
Idiopathic Thrombocytopenic Purpura
B cell lymphoproliferative disorder
Systemic disease Sarcoidosis
Legionella Infection
Systemic lupus erythematosus
Rheumatoid arthritis
Relapsing polychondritis
Diseases Headache Fever Weight loss Arthralgia Claudication Bruit HTN Focal neurological disorder Biomarker CBC ESR Other CT scan Angiography Ultrasound Other Histopathology Gold standard Additional findings
Variable-vessel vasculitis Behçet’s syndrome
Cogan's syndrome
Gastrointestinal disease Inflammatory Bowel Disease
Whipple's disease
Sjögren's syndrome
Single-organ vasculitis Primary central nervous system vasculitis
Infectious disease Aspergillosis
Histoplasmosis
Herpes Simplex Encephalitis
Systemic disease Eclampsia
Fibromuscular Dysplasia

References

  1. Vaideeswar P, Deshpande JR (2013). "Pathology of Takayasu arteritis: A brief review". Ann Pediatr Cardiol. 6 (1): 52–8. doi:10.4103/0974-2069.107235. PMC 3634248. PMID 23626437.
  2. Calvo-Romero JM (2003). "Giant cell arteritis". Postgrad Med J. 79 (935): 511–5. PMC 1742823. PMID 13679546.
  3. Stafa A, Leonardi M (2008). "Role of neuroradiology in evaluating cerebral aneurysms". Interv Neuroradiol. 14 Suppl 1: 23–37. doi:10.1177/15910199080140S106. PMC 3328052. PMID 20557771.
  4. Cassiman C, Casteels I, Stalmans P, Legius E, Jacob J (2017). "Optical Coherence Tomography Angiography of Retinal Microvascular Changes Overlying Choroidal Nodules in Neurofibromatosis Type 1". Case Rep Ophthalmol. 8 (1): 214–220. doi:10.1159/000469702. PMC 5422752. PMID 28512424.
  5. Evans, D G. R (2000). "Neurofibromatosis type 2". Journal of Medical Genetics. 37 (12): 897–904. doi:10.1136/jmg.37.12.897. ISSN 1468-6244.
  6. Plouin PF, Perdu J, La Batide-Alanore A, Boutouyrie P, Gimenez-Roqueplo AP, Jeunemaitre X (2007). "Fibromuscular dysplasia". Orphanet J Rare Dis. 2: 28. doi:10.1186/1750-1172-2-28. PMC 1899482. PMID 17555581.
  7. Gazit Y, Jacob G, Grahame R (2016). "Ehlers-Danlos Syndrome-Hypermobility Type: A Much Neglected Multisystemic Disorder". Rambam Maimonides Med J. 7 (4). doi:10.5041/RMMJ.10261. PMC 5101008. PMID 27824552.
  8. Michet CJ, Matteson EL (2008). "Polymyalgia rheumatica". BMJ. 336 (7647): 765–9. doi:10.1136/bmj.39514.653588.80. PMC 2287267. PMID 18390527.
  9. Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.

Template:WH Template:WS